Materials and methods directed to asparagine synthetase and...

Details Materials and methods directed to asparagine synthetase and... Materials and methods directed to asparagine synthetase and...

2011-07-26

2011-07-26

Bowman, Amy (Department: 1635)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C536S024500, C530S387100

Reexamination Certificate

active

07985548

ABSTRACT:
Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.

REFERENCES:
patent: 4450150 (1984-05-01), Sidman
patent: 5169939 (1992-12-01), Gefter et al.
patent: 5643759 (1997-07-01), Pfreundschuh
patent: 5750078 (1998-05-01), Shitara et al.
patent: 6020153 (2000-02-01), Hardman et al.
patent: 6420113 (2002-07-01), Buechler et al.
patent: 6423511 (2002-07-01), Nakamura et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6800738 (2004-10-01), Carter et al.
patent: WO 2006/095270 (2006-09-01), None
Aagaard et al., Epub, 1-8, Feb. 20, 2007;Molecular Therapy, 15, 938-945 (2007).
Alley et al.,Cancer Res., 48, 589-601 (1988).
Batist et al.,J. Biol. Chem., 261 (33), 15544-15549 (1986).
Boehlein et al.,Biochemistry, 40,11168-11175 (2001).
Bolhuis et al.,Cancer Immunol. Immunother., 34, 1-8 (1991).
Bussey et al.,Mol. Cancer Ther., 5 (4), 853-867 (2006).
Carter et al.,J. Hematotherapy, 4, 463-470 (1995).
Cowan et al.,Proc. Natl. Acad. Sci. USA, 83, 9328-9332 (1986).
Ding et al.,Leukemia, 19, 420-426 (2005).
Engels et al.,Angew. Chem. Int. Ed. Engl., 28, 716-734 (1989).
Fine et al.,Cancer Res., 65 (1), 291-299 (2005).
Gutierrez et al.,Chemistry and Biology, 13, 1339-1347 (2006).
Hak et al.,Leukemia, 18, 1072-1077 (2004).
International Search Report PCT/US2007/005555.
Karlin et al.,Proc. Natl. Acad. Sci. USA, 87, 2264-2268 (1990).
Karlin et al.,Proc. Natl. Acad. Sci. USA, 90, 5873-5877 (1993).
Kononen et al.,Nat. Med., 4 (7), 844-847 (1998).
Koroniak et al.,Organic Letters, 5 (12), 2033-2036 (2003).
Krejci et al.,Leukemia, 18, 434-441 (2004).
Lorenzi et al., 97thAACR Annual Meeting, Abstract 3122 (2006).
Lorenzi et al.,Mol. Cancer Ther., 5 (11), 2613-2623 (2006).
Ludwig,Nat. Rev. Cancer, 5, 845-856 (2005).
Omim No. 108370 (1986).
Pluckthun et al.,Immunotechnology, 3, 83-105 (1997).
Renner et al.,Immunological Rev., 145, 179-209 (1995).
Richards et al.,Annu. Rev. Biochem., 75, 629-654 (2006).
Ross et al.,Nat. Genet., 24, 227-235 (2000).
Scherf et al.,Nat. Genet., 24, 236-244 (2000).
Segal et al.,Immunobiology, 185, 390-402 (1992).
Segal et al.,J. Hematotherapy, 4, 377-382 (1995).
Staunton et al.,Proc. Natl. Acad. Sci. USA, 98, 10787-10792 (2001).
Teicher,Methods in Molecular Medicine, 85, 297-321 (2003).
Entrez Gene ID No. 440, Aug. 28, 2008.
GenBank Accession No. AAA36781, Aug. 3, 1993.
GenBank Accession No. AAA51789, Oct. 31, 1994.
GenBank Accession No. AAA52756, Nov. 9, 1994.
GenBank Accession No. AAA63266, Mar. 9, 1995.
GenBank Accession No. AAH08723, Jul. 15, 2006.
GenBank Accession No. AAH14621, Jul. 15, 2006.
GenBank Accession No. AAP35777, May 13, 2003.
GenBank Accession No. AAQ96856, Oct. 15, 2003.
GenBank Accession No. AC079781, Oct. 15, 2003.
GenBank Accession No. AK000379, Sep. 12, 2006.
GenBank Accession No. BC008723, Jul. 15, 2006.
GenBank Accession No. BC014621, Jul. 15, 2006.
GenBank Accession No. BC030024, Aug. 4, 2006.
GenBank Accession No. BG718826, updated May 8, 2001.
GenBank Accession No. BT007113, May 13, 2003.
GenBank Accession No. CH236949, Aug. 10, 2004.
GenBank Accession No. EAL24115, Aug. 10, 2004.
GenBank Accession No. L35946, Nov. 9, 1994.
GenBank Accession No. M15798, Aug. 3, 1993.
GenBank Accession No. M27054, Mar. 7, 1995.
GenBank Accession No. M27396, Oct. 31, 1994.
GenBank Accession No. NM—001673, Feb. 21, 2008.
GenBank Accession No. NM—133436, Feb. 21, 2008.
GenBank Accession No. NM—183356, Feb. 21, 2008.
GenBank Accession No. NP—001664, Feb. 21, 2008.
GenBank Accession No. NP—597680, Feb. 21, 2008.
GenBank Accession No. NP—899199, Feb. 21, 2008.
Ando et al., “Selective apoptosis of natural killer-cell tumours by I-asparaginase,”Br. J. Haematol., 130 (6), 860-868 (2005).
Appel et al., “Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia,”Blood, 107 (11), 4244-4249 (2006).
Aslanian et al., “Asparagine synthetase expression alone is sufficient to induce I-asparaginase resistance in MOLT-4 human leukaemia cells,”Biochem. J., 357, 321-328 (2001).
Aslanian et al., “Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells,”Biochem. J., 358, 59-67 (2001).
Capizzi et al., “Sequential high-dose ara-C and asparaginase versus high-dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias,”Semin. Oncol., 14 (2 Suppl 1), 40-50 (1987).
Ciustea et al., “Efficient expression, purification, and characterization of C-terminally tagged, recombinant human asparagine synthetase,”Arch. Biochem. Biophys., 440 (1),18-27 (2005).
Gantt et al., “Elevated levels of asparagine synthetase activity in physiologically and genetically derepressed Chinese hamster ovary cells are due to increased rates of enzyme synthesis,”J. Biol. Chem., 256 (14), 7311-7315 (1981).
Keating et al., “L-asparaginase and PEG asparaginase—past, present, and future,”Leuk. Lymphoma., 10 Suppl., 153-157 (1993)—Abstract Only.
Leslie et al., “Expression levels of asparagine synthetase in blasts fromchildrenand adults with acute lymphoblastic leukaemia,”Br. J. Haematol., 132 (6), 740-742 (2006).
Lorenzi et al., “Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines,”Mol. Cancer Ther., 7 (10), 3123-3128 (2008).
Maul et al., “Methotrexate stimulation of asparagine synthetase activity in rat liver,”Life Sci., 30 (12), 1051-1057 (1982).
Nandy et al., “The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis,”Anticancer Res., 18 (2A), 727-737 (1998).
Rotoli et al., “Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells,”Cell Physiol Biochem., 15, 281-292 (2005).
Sakamoto et al., “Temporary effective treatment with L-asparaginase for a patient with refractory nasal NK/T-cell lymphoma,” Gan to Kagaku Ryoho 32(12):1993-6 (2005)—Abstract Only.
Siu et al., “CCAAT/enhancer-binding protein-beta is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene,”J. Biol. Chem., 276, 48100-48107 (2001).
Stams et al., “Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL,”Blood, 101, 2743-2747 (2003).
Stams et al., “Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia,”Blood, 105, 4223-4225 (2005).
Uren et al., “Effects of asparagine synthetase inhibitors on asparaginase resistant tumors,”Biochem. Pharmacol., 26 (15), 1405-1410 (1977).
Worton et al., “Hypomethylation and reactivation of the asparagine synthetase gene induced by L-asparaginase and ethyl methanesulfonate,”Cancer Res., 51 (3), 985-989 (1991).

Affiliated with

Also associated with

Rating

Materials and methods directed to asparagine synthetase and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Materials and methods directed to asparagine synthetase and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods directed to asparagine synthetase and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2724229